EMA prepares guidance on stem cell-based medicines
This article was originally published in Scrip
The European Medicines Agency has drawn up some ideas for future guidance on stem cell-containing medicines, with a focus on issues such as the ability of human embryonic stem cells to form teratomas and the need for long-term follow-up of efficacy and safety. The ideas are contained in a "reflection paper" that interested parties are invited to comment on by 30 June.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.